Hannelore V Heemers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1982191/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention. Cells, 2022, 11, 936.	4.1	6
2	Genomic alterations impact cell cycle-related genes during prostate cancer progression. Endocrine-Related Cancer, 2021, 28, L5-L10.	3.1	1
3	Novel insights in cell cycle dysregulation during prostate cancer progression. Endocrine-Related Cancer, 2021, 28, R141-R155.	3.1	16
4	Treatment-induced Treatment Sensitization in Metastatic Castration-resistant Prostate Cancer. European Urology, 2021, 79, 734-735.	1.9	2
5	Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer. Cancers, 2021, 13, 3947.	3.7	5
6	Androgen receptor co-regulation in prostate cancer. Asian Journal of Urology, 2020, 7, 219-232.	1.2	28
7	Diversity in Androgen Receptor Action Among Treatment-naÃ ⁻ ve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. European Urology Open Science, 2020, 22, 34-44.	0.4	7
8	AR-dependent phosphorylation and phospho-proteome targets in prostate cancer. Endocrine-Related Cancer, 2020, 27, R193-R210.	3.1	7
9	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	5.9	8
10	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	1.9	105
11	Functional Studies on Steroid Receptors. Methods in Molecular Biology, 2018, 1786, 117-130.	0.9	0
12	Androgen Signaling in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030452.	6.2	278
13	Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. European Urology, 2017, 71, 183-192.	1.9	171
14	Lipid degradation promotes prostate cancer cell survival. Oncotarget, 2017, 8, 38264-38275.	1.8	64
15	A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. ELife, 2017, 6, .	6.0	49
16	GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models. Clinical Cancer Research, 2016, , clincanres.0137.2016.	7.0	3
17	Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action. Database: the Journal of Biological Databases and Curation, 2016, 2016, .	3.0	20
18	Targeting Androgen Receptor Action for Prostate Cancer Treatment: Does the Post-Receptor Level Provide Novel Opportunities?. International Journal of Biological Sciences, 2014, 10, 576-587.	6.4	16

HANNELORE V HEEMERS

#	Article	IF	CITATIONS
19	Re: Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology, 2014, 66, 597.	1.9	2
20	Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression. Current Drug Targets, 2013, 14, 481-489.	2.1	2
21	RhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells. Molecular Endocrinology, 2012, 26, 716-735.	3.7	51
22	Identification of a Clinically Relevant Androgen-Dependent Gene Signature in Prostate Cancer. Cancer Research, 2011, 71, 1978-1988.	0.9	38
23	Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate, 2010, 70, 959-970.	2.3	22
24	Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer. , 2010, , 41-51.		2
25	Androgen Modulation of Coregulator Expression in Prostate Cancer Cells. Molecular Endocrinology, 2009, 23, 572-583.	3.7	64
26	Unraveling the Complexities of Androgen Receptor Signaling in Prostate Cancer Cells. Cancer Cell, 2009, 15, 245-247.	16.8	32
27	The Role of the Transcriptional Coactivator p300 in Prostate Cancer Progression. Advances in Experimental Medicine and Biology, 2008, 617, 535-540.	1.6	28
28	Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer. Cancer Research, 2007, 67, 10592-10599.	0.9	61
29	Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells. Cancer Research, 2007, 67, 3422-3430.	0.9	101
30	Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex. Endocrine Reviews, 2007, 28, 778-808.	20.1	615
31	Androgen Activation of the Sterol Regulatory Element-Binding Protein Pathway: Current Insights. Molecular Endocrinology, 2006, 20, 2265-2277.	3.7	110
32	Androgen Receptor Coregulatory Proteins as Potential Therapeutic Targets in the Treatment of Prostate Cancer. Current Cancer Therapy Reviews, 2005, 1, 175-186.	0.3	18
33	Identification of an Androgen Response Element in Intron 8 of the Sterol Regulatory Element-binding Protein Cleavage-activating Protein Gene Allowing Direct Regulation by the Androgen Receptor. Journal of Biological Chemistry, 2004, 279, 30880-30887.	3.4	58
34	Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Molecular and Cellular Endocrinology, 2003, 205, 21-31.	3.2	65
35	Androgens Stimulate Lipogenic Gene Expression in Prostate Cancer Cells by Activation of the Sterol Regulatory Element-Binding Protein Cleavage Activating Protein/Sterol Regulatory Element-Binding Protein Pathway. Molecular Endocrinology, 2001, 15, 1817-1828.	3.7	140
36	Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene, 2000, 19, 5173-5181.	5.9	161